Immuneering Corporation
General ticker "IMRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $246.9M (TTM average)
Immuneering Corporation does not follow the US Stock Market performance with the rate: -22.6%.
Estimated limits based on current volatility of 3.5%: low 3.47$, high 3.72$
Factors to consider:
- Total employees count: 53 (-19.7%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Construction delays, Inability to raise capital, Cybersecurity threats
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.62$, 9.03$]
- 2026-12-31 to 2027-12-31 estimated range: [2.59$, 6.78$]
Financial Metrics affecting the IMRX estimates:
- Positive: with PPE of -4.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 94.18 > 81.92
- Negative: Investing cash flow per share per price, % of -30.81 <= -18.95
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: -0.37 < Inventory ratio change, % of 0
Short-term IMRX quotes
Long-term IMRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $58.41MM | $64.07MM | $59.38MM |
| Operating Income | $-58.41MM | $-64.07MM | $-59.38MM |
| Non-Operating Income | $4.94MM | $3.03MM | $3.35MM |
| R&D Expense | $41.62MM | $47.96MM | $42.05MM |
| Income(Loss) | $-53.47MM | $-61.04MM | $-56.02MM |
| Net Income(Loss)* | $-53.47MM | $-61.04MM | $-56.02MM |
| Stockholders Equity | $90.58MM | $41.39MM | $218.48MM |
| Assets | $102.58MM | $52.71MM | $231.99MM |
| Operating Cash Flow | $-48.97MM | $-55.00MM | $-45.34MM |
| Capital expenditure | $0.34MM | $0.08MM | $0.14MM |
| Investing Cash Flow | $7.30MM | $26.43MM | $-88.74MM |
| Financing Cash Flow | $28.44MM | $5.30MM | $226.58MM |
| Earnings Per Share** | $-1.88 | $-2.04 | $-1.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.